Economic evaluations of genetic applications recognize three categories of BRCA1/2 genetic testing programs as cost-effective: (i) population-based screening among Ashkenazi Jews; (ii) family history-based screening, although methods on how to select high-risk women from the general population and the related cost are not detailed in literature studies; and (iii) cancer-based genetic screening, which includes tools for the identification of affected women at higher risk of inherited breast and ovarian cancers (D'Andrea et al., 2016). Here, BRCA1 is linked to ovarian carcinoma.